Dual GLP-1 / GIP Receptor Agonist
Tirzepatide is a first-in-class synthetic 39-amino-acid polypeptide engineered as a balanced dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Developed by Eli Lilly and Company, it was first described in the scientific literature in 2018 and received FDA approval in May 2022 under the trade name Mounjaro for type 2 diabetes, followed by approval as Zepbound for chronic weight management in November 2023. Unlike selective GLP-1 receptor agonists such as semaglutide, tirzepatide activates both incretin receptors with approximately equal potency — a pharmacological profile that produces distinct downstream effects on insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation. The GIP receptor component is believed to enhance the metabolic benefits beyond what GLP-1 agonism alone can achieve, particularly in adipose tissue biology and lipid metabolism. The compound incorporates a C20 fatty diacid moiety attached via a linker to Lys20, enabling non-covalent albumin binding that extends the plasma half-life to approximately 5 days. This engineering permits once-weekly subcutaneous dosing. In the landmark SURMOUNT-1 trial, the 15 mg dose produced a mean body weight reduction of 22.5% at 72 weeks — the largest weight loss observed with any single pharmacological agent in a randomized controlled trial.
Simultaneously engages GLP-1 and GIP receptors, producing synergistic metabolic effects not achievable with selective agonists.
SURMOUNT-1 demonstrated 22.5% mean weight loss at 72 weeks — the highest of any monotherapy agent in clinical trials.
SURPASS trials showed HbA1c reductions of 2.0–2.6% across dose levels, with a significant proportion of subjects achieving normoglycemia.
SURPASS-CVOT demonstrated a 10% reduction in major adverse cardiovascular events (MACE) compared to dulaglutide.
Significant reductions in triglycerides, VLDL, and apolipoprotein B observed across clinical trials.
The ~5-day half-life from albumin binding permits once-weekly subcutaneous administration.
SYNERGY-NASH trial data showed significant reduction in liver fat content and NASH resolution in a substantial proportion of participants.
GIP receptor activation in adipocytes may promote favorable changes in fat distribution and adipokine signaling.
Tirzepatide exerts its effects through balanced co-agonism of the GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), both of which are class B G protein-coupled receptors (GPCRs). Upon binding, the peptide activates adenylyl cyclase via Gαs coupling, increasing intracellular cyclic AMP (cAMP) and triggering downstream protein kinase A (PKA) signaling cascades. At the pancreatic level, GLP-1R activation on beta cells potentiates glucose-dependent insulin secretion through closure of KATP channels and increased calcium influx. Simultaneously, GLP-1R agonism suppresses glucagon release from alpha cells. The GIPR co-agonism amplifies insulin secretion through an independent cAMP pathway and may protect beta cells from glucolipotoxicity-induced apoptosis. Centrally, tirzepatide activates GLP-1 receptors in the hypothalamic arcuate nucleus and area postrema, reducing appetite through POMC/CART neuron activation and NPY/AgRP neuron inhibition. The GIP receptor component activates neurons in the hypothalamus and hindbrain that are not responsive to GLP-1 alone, potentially explaining the enhanced weight loss efficacy. The compound also slows gastric emptying via vagal afferent signaling, prolonging postprandial satiety. Peripheral effects include enhanced lipid oxidation in skeletal muscle and hepatocytes, reduced de novo lipogenesis, and adipose tissue remodeling — with emerging evidence that GIPR activation promotes adipocyte differentiation and healthier fat distribution patterns.
Investigating the synergistic effects of dual incretin receptor activation on insulin resistance, dyslipidemia, and visceral adiposity.
ActiveSYNERGY-NASH trial evaluating hepatic steatosis resolution and fibrosis improvement through dual incretin signaling.
Phase 2 CompleteSURPASS-CVOT assessed MACE reduction in type 2 diabetes patients with established cardiovascular disease.
Phase 3 CompleteSUMMIT trial evaluating functional capacity and heart failure outcomes in HFpEF patients with obesity.
Phase 3 CompleteSURMOUNT-OSA studying effects on apnea-hypopnea index (AHI) and sleep architecture in obese subjects.
Phase 3 CompleteComparative studies of GIP+GLP-1 co-agonism vs selective GLP-1 agonism for understanding receptor crosstalk mechanisms.
Active| Period | Dose | Frequency | Notes |
|---|---|---|---|
| 1–4 | 2.5 mg | Once weekly | Initiation dose — minimizes GI side effects |
| 5–8 | 5 mg | Once weekly | First escalation — assess tolerance |
| 9–12 | 7.5 mg | Once weekly | Intermediate step (optional per protocol) |
| 13–16 | 10 mg | Once weekly | Second target dose — may maintain here |
| 17–20 | 12.5 mg | Once weekly | Intermediate step before maximum dose |
| 21+ | 15 mg | Once weekly | Maximum studied dose — highest efficacy in SURMOUNT-1 |
Tirzepatide activates both GLP-1 and GIP receptors simultaneously, whereas semaglutide is a selective GLP-1 receptor agonist. The SURPASS-2 trial directly compared the two: tirzepatide 15 mg produced significantly greater HbA1c reduction (-2.46% vs -1.86%) and weight loss (-12.4 kg vs -6.2 kg) than semaglutide 1 mg at 40 weeks. The dual mechanism is believed to engage additional metabolic pathways not accessible through GLP-1 agonism alone.
Reconstitute lyophilized tirzepatide with bacteriostatic water at a concentration of 1–2 mg/mL. Inject the solvent slowly against the vial wall to avoid foaming, then swirl gently — never shake. The reconstituted solution should appear clear and colorless. Store at 2–8°C (standard refrigerator) and use within 28 days.
The 4-week escalation steps are designed to mitigate gastrointestinal side effects, primarily nausea and diarrhea, which are dose-dependent. Clinical trials showed that slower titration significantly reduces the incidence and severity of GI adverse events compared to rapid escalation. Most GI symptoms occur during dose increases and attenuate with continued use at each dose level.
The SURPASS program (types 1–5) evaluated efficacy in type 2 diabetes, while SURMOUNT (1–4) focused on obesity. SURMOUNT-1 (n=2,539) showed 22.5% mean weight reduction at 72 weeks. SURPASS-2 demonstrated superiority over semaglutide 1 mg. Additional ongoing programs include SYNERGY-NASH (liver disease) and SUMMIT (heart failure with preserved ejection fraction).
Unreconstituted lyophilized powder should be stored at -20°C for long-term storage (up to 24 months) or at 2–8°C for medium-term storage (up to 12 months). Once reconstituted, store at 2–8°C and use within 28 days. Protect from direct light. Do not freeze reconstituted solution. Avoid repeated freeze-thaw cycles of the lyophilized powder.
In research settings, tirzepatide has been studied alongside metformin, SGLT2 inhibitors, and insulin. Combining with other GLP-1 agonists is generally avoided due to overlapping receptor activity. Combining with GHRH analogs or GHRPs is an area of emerging interest, but no published data exists on these specific combinations. Each combination should be evaluated individually for receptor competition and pharmacokinetic interactions.
Need help choosing a peptide?
Try the AI Coach →